MegaMD Co., Ltd.

As of June 30, 2026, MegaMD Co., Ltd. carries a market capitalization of 30.75B, placing it among publicly traded companies globally. Its enterprise value stands at -15.06B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, MegaMD Co., Ltd. has 22.07M shares outstanding.

As of June 30, 2026, MegaMD Co., Ltd. trades at a trailing price-to-earnings ratio of 6.10. The price-to-sales ratio is 0.93, and the price-to-book ratio stands at 0.45.

As of June 30, 2026, MegaMD Co., Ltd. maintains a current ratio of 3.14, meaning it holds 3.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 3.00, indicating elevated leverage, while an interest coverage ratio of 44.13 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, MegaMD Co., Ltd. posted a return on equity (ROE) of 7.52, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 2.42 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 5.85, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 7.41, useful for judging operating efficiency across full business cycles. The company generates approximately 210.74M in revenue per employee across its workforce of 157.75, a quick read on workforce productivity versus industry peers. Inventory turnover of 43.15 indicates how many times MegaMD Co., Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, MegaMD Co., Ltd. recorded 1.61B in income tax expense. That works out to an effective tax rate of 24.19, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 6.66B, leaving 5.05B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 23, 2026, MegaMD Co., Ltd.'s stock has declined approximately 31.92% over the past 52 weeks. The 50-day moving average sits at 1,420.68, while the 200-day moving average is 1,614.87.

Over the twelve months ended June 30, 2026, MegaMD Co., Ltd. generated 33.24B in revenue and converted that into 5.05B in net income, yielding earnings per share of 228.39. EBITDA reached 7.31B, while operating income came in at 2.35B.

As of June 30, 2026, MegaMD Co., Ltd. holds 47.86B in cash and equivalents against 2.05B in total debt, resulting in a net debt position of -14.51B. Total book value stands at 68.53B, with working capital of 34.75B providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, MegaMD Co., Ltd. posted a gross margin of 59.87, reflecting its pricing power and cost economics. The operating margin of 7.07 and net profit margin of 15.18 provide insight into operational efficiency.

As of June 30, 2026, MegaMD Co., Ltd. has an Altman Z-Score of 2.81, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.